You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. AIVIS: Next Generation Vigilant Information Seeking Artificial Intelligence-based Clinical Decision Support for Sepsis

    SBC: Healcisio, Inc.            Topic: NIAID

    Abstract Sepsis, a heterogeneous syndrome characterized by whole-body inflammation caused by the body's response to an infection, is the most expensive and deadly condition treated in hospitals, with over 270,000 cases of sepsis-related deaths in the U.S. alone. The cornerstones of optimal sepsis care are early recognition accompanied by appropriate antimicrobial therapy, and use of evidence-based ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Fluorescence lifetime imaging device for 5-ALA-guided neurosurgery

    SBC: HILIGHT SURGICAL, INC.            Topic: 394

    PROJECT SUMMARY 5-ALA-induced PpIX fluorescence-guided surgery (FGS) enables real-time visualization of residual cancer tissue during resection of brain tumors. This addresses a critical need in surgical oncology as the ability to identify residual tumor leads to improvements in overall survival, whereas the sparing of normal tissue benefits the patient’s quality of life. Currently, surgeons vis ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Nanopore Array for Multiparameter Analysis of Single Extracellular Vesicles

    SBC: ELECTRONIC BIOSCIENCES, INC.            Topic: NIGMS

    Project Summary Today, researchers and clinicians, in academia and industry, lack the tools and technologies needed to accurately characterize, differentiate, and sort extracellular vesicles (EVs); currently available technologies were simply not developed to characterize entities smaller than 200 nanometers in size. While the importance of EVs in directing cargo delivery for intercellular communi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Novel Highly Regenerative and Scalable Progenitor Cell Exosomes for Treating Peripheral Artery Disease

    SBC: AGEX THERAPEUTICS INC            Topic: NHLBI

    ABSTRACT Peripheral artery disease (PAD) is associated with vascular obstructions in the extremities, leading to intermittent claudication, ischemic ulcers, leg pain at rest, and amputation. In the US, approximately 6.5 million people have peripheral artery disease (PAD), affecting 12-20% of people over 60 years of age . Current cell therapies to restore limb perfusion have shown only moderate ben ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Chondrofluid for arthroscopic knee cartilage repair

    SBC: CARTILAGE INC            Topic: NIAMS

    PROJECT SUMMARY Minor injuries to articular cartilage can initiate a catabolic cascade, causing small defects to progress into larger, more symptomatic defects. Pain, lesion progression, and accelerated joint deterioration may be avoided with strategies that repair small defects with hyaline-like cartilage. The repair of chondral defects using arthroscopic techniques, performed in a minimally inva ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Factor H Fc fusions as novel therapeutics for Burkholderia pseudomallei infections

    SBC: Planet Biotechnology Incorporated            Topic: NIAID

    Burkholderia pseudomallei (Bp) is the causative agent of melioidosis, a major cause of morbidity and septic death in tropical/subtropical regions worldwide. It is particularly virulent in diabetic patients and is also considered a Tier 1 select agent due to its potential use as a bioweapon. These bacteria are naturally resistant to many antibiotics and there are currently no vaccines available. Th ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Wearable Array for Ultrasound Stimulation on the Retina

    SBC: Phononz Inc            Topic: NEI

    Retinal degeneration involving progressive deterioration and loss of function of photoreceptors is a major cause of permanent vision loss worldwide. Strategies to treat these incurable conditions incorporate retinal prostheses via electrically stimulating surviving retinal neurons with implanted devices in the eye, optogenetic therapy, and sonogenetic therapy. Existing challenges of these strategi ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a first-in-class antiviral to address CMV drug resistance in immunocompromised patients

    SBC: VXBIOSCIENCES, INC.            Topic: NIAID

    ABSTRACT Human cytomegalovirus (CMV) infects a majority of the world’s population and is a leading cause of disease in transplant patients and newborns, accounting for more congenital birth defects than Down’s syndrome, spina bifida, or fetal alcohol syndrome. There is no approved vaccine and all current antiviral therapies for CMV prevention or treatment suffer from toxicity and a low barrier ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Miniaturized AD/ADRD Microphysiological Systems Platform for High-throughput Screening

    SBC: NEUCYTE INC            Topic: NIA

    Abstract Alzheimer Disease (AD) is characterized by b-amyloid (Ab) accumulation, neurofibrillary tangles (NFTs), neuroinflammation, and widespread neuronal and synaptic loss. To date, there are no therapies available, although immunotherapies i.e., Lecanemab hold promise. Species differences underlie the difficulties in translating therapeutics uncovered in animal models for human brain-specific d ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Novel probiotics to mitigate xenobiotic toxicity through microbial biotransformation

    SBC: NEXILICO, INC.            Topic: NIEHS

    PROJECT SUMMARY / ABSTRACT The human gut microbiome consists of trillions of microorganisms which metabolize a variety of xenobiotic compounds, including environmental chemicals, thereby affecting their overall toxicity to the host organism. Gut microorganisms can either increase or decrease the toxicity of xenobiotic compounds based on reactions with microbial enzymes, which is referred to as Mic ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government